XML 27 R37.htm IDEA: XBRL DOCUMENT v2.4.1.9
SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details)
In Thousands, except Share data, unless otherwise specified
 12 Months Ended 12 Months Ended
Dec. 31, 2014
USD ($)
item
Dec. 31, 2013
USD ($)
Dec. 31, 2012
USD ($)
Dec. 31, 2014
Neviah [Member]
USD ($)
Dec. 31, 2014
Neviah [Member]
Merck Holdings [Member]
Convertible Bridge Loan Agreement [Member]
EUR (€)
Dec. 31, 2014
Keddem [Member]
Dec. 31, 2014
Options [Member]
Dec. 31, 2013
Options [Member]
Dec. 31, 2012
Options [Member]
Dec. 31, 2014
Warrants [Member]
Dec. 31, 2013
Warrants [Member]
Dec. 31, 2012
Warrants [Member]
Dec. 31, 2013
Exchange Option [Member]
SIGNIFICANT ACCOUNTING POLICIES [Abstract]                          
Average interest rate, short-term bank deposits in U.S. dollars 0.85%cgen_ShortTermBankDepositsWeightedAverageRateForeign 0.63%cgen_ShortTermBankDepositsWeightedAverageRateForeign                      
Marketable securities impairment losses $ 0us-gaap_ImpairmentOfInvestments $ 0us-gaap_ImpairmentOfInvestments $ 0us-gaap_ImpairmentOfInvestments                    
Evogene shares held 113,405cgen_FairValueMethodInvestmentNumberOfSharesHeld 232,292cgen_FairValueMethodInvestmentNumberOfSharesHeld                      
Average interest rate, long-term bank deposits in U.S. dollars 1.02%cgen_LongTermBankDepositsWeightedAverageRateDomestic                        
Deferred revenue 1,789us-gaap_DeferredRevenue 6,711us-gaap_DeferredRevenue                      
Number of licensed programs to achieve substantive milestones revenues 1cgen_NumberOfLicensedProgramsToAchieveSubstantiveMilestonesRevenues                        
Revenue recognition under milestone method 7,200us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized                        
Severance expenses 344us-gaap_SeveranceCosts1 294us-gaap_SeveranceCosts1 252us-gaap_SeveranceCosts1                    
Derivative, notional amount 5,626invest_DerivativeNotionalAmount                        
Derivative, contract period 9 months                        
Derivative, maturity date Sep. 30, 2015                        
Unrealized gains arising from derivative contracts 141us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax                          
Derivative related expenses 0cgen_DerivativeRelatedExpense                        
Fair value of outstanding forward contracts 141us-gaap_DerivativeFairValueOfDerivativeNet                        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]                          
Number of shares             6,363,348us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
/ us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis
= us-gaap_StockOptionMember		 6,271,819us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
/ us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis
= us-gaap_StockOptionMember		 6,170,554us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
/ us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis
= us-gaap_StockOptionMember		 333,333us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
/ us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis
= us-gaap_WarrantMember		 500,000us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
/ us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis
= us-gaap_WarrantMember		 500,000us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
/ us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis
= us-gaap_WarrantMember		 2,157,293us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
/ us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis
= cgen_ExchangeOptionMember
Schedule of Equity Method Investments [Line Items]                          
Number of investments in affiliates 2cgen_EquityMethodInvestmentNumberOfInvestmentsInAffiliates                        
Ownership percentage       25.12%us-gaap_EquityMethodInvestmentOwnershipPercentage
/ us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis
= cgen_NeviahGenomicsLtdMember		   36.00%us-gaap_EquityMethodInvestmentOwnershipPercentage
/ us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis
= cgen_KeddemBioScienceLtdMember		              
Face amount         500us-gaap_DebtInstrumentFaceAmount
/ us-gaap_CounterpartyNameAxis
= cgen_MerckHoldingsNetherlandsBVMember
/ us-gaap_DebtInstrumentAxis
= cgen_ConvertibleBridgeLoanAgreementMember
/ us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis
= cgen_NeviahGenomicsLtdMember		                
Loan grant date         Dec. 17, 2014                
Investment amount       155us-gaap_EquityMethodInvestmentAggregateCost
/ us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis
= cgen_NeviahGenomicsLtdMember		                  
Maturity term         18 months                
Interest rate (as a percent)         2.00%us-gaap_DebtInstrumentInterestRateStatedPercentage
/ us-gaap_CounterpartyNameAxis
= cgen_MerckHoldingsNetherlandsBVMember
/ us-gaap_DebtInstrumentAxis
= cgen_ConvertibleBridgeLoanAgreementMember
/ us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis
= cgen_NeviahGenomicsLtdMember		                
Equity losses $ (155)us-gaap_IncomeLossFromEquityMethodInvestments       $ (155)us-gaap_IncomeLossFromEquityMethodInvestments
/ us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis
= cgen_NeviahGenomicsLtdMember